Goldman Sachs Delivers a Blow to Alnylam’s Stock

The biotechnology sector was rattled by an unexpected development yesterday. In a move that caught investors off guard, Goldman Sachs removed Alnylam Pharmaceuticals from its prestigious Conviction List, triggering a sharp decline in the share price of this RNAi therapy pioneer. This decision arrives just days after the company posted exceptionally strong quarterly results, leaving market participants to question whether this analyst action signals deeper concerns beyond temporary market jitters.

The timing of Goldman Sachs’ revision appears particularly inopportune. Alnylam had recently dazzled the market with spectacular third-quarter performance, reporting adjusted earnings of $2.90 per share—more than double analyst expectations. Revenue surged to $1.25 billion, with investors particularly encouraged by the Read more...